Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105.

Liu Y, Starr MD, Brady JC, Rushing C, Pang H, Adams B, Alvarez D, Theuer CP, Hurwitz HI, Nixon AB.

Mol Cancer Ther. 2018 Oct;17(10):2248-2256. doi: 10.1158/1535-7163.MCT-17-0916. Epub 2018 Jul 11.

PMID:
29997150
2.

Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular Carcinoma.

Ronald J, Nixon AB, Marin D, Gupta RT, Janas G, Chen W, Suhocki PV, Pabon-Ramos W, Sopko DR, Starr MD, Brady JC, Hurwitz HI, Kim CY.

Radiology. 2017 Oct;285(1):311-318. doi: 10.1148/radiol.2017162555. Epub 2017 Aug 8.

PMID:
28787261
3.

Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).

Hatch AJ, Sibley AB, Starr MD, Brady JC, Jiang C, Jia J, Bowers DL, Pang H, Owzar K, Niedzwiecki D, Innocenti F, Venook AP, Hurwitz HI, Nixon AB; Alliance for Clinical Trials in Oncology.

Cancer Med. 2016 Sep;5(9):2249-60. doi: 10.1002/cam4.806. Epub 2016 Jul 27.

4.

Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus.

Liu Y, Starr MD, Brady JC, Rushing C, Bulusu A, Pang H, Honeycutt W, Amara A, Altomare I, Uronis HE, Hurwitz HI, Nixon AB.

Mol Cancer Ther. 2015 Apr;14(4):1048-56. doi: 10.1158/1535-7163.MCT-14-0923-T. Epub 2015 Feb 18.

5.

Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.

Rangwala F, Bendell JC, Kozloff MF, Arrowood CC, Dellinger A, Meadows J, Tourt-Uhlig S, Murphy J, Meadows KL, Starr A, Broderick S, Brady JC, Cushman SM, Morse MA, Uronis HE, Hsu SD, Zafar SY, Wallace J, Starodub AN, Strickler JH, Pang H, Nixon AB, Hurwitz HI.

Invest New Drugs. 2014 Aug;32(4):700-9. doi: 10.1007/s10637-014-0089-2. Epub 2014 Apr 9.

6.

Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer.

Liu Y, Starr MD, Brady JC, Dellinger A, Pang H, Adams B, Theuer CP, Lee NY, Hurwitz HI, Nixon AB.

Cancer Med. 2014 Jun;3(3):580-91. doi: 10.1002/cam4.207. Epub 2014 Feb 14.

7.

Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.

Strickler JH, McCall S, Nixon AB, Brady JC, Pang H, Rushing C, Cohn A, Starodub A, Arrowood C, Haley S, Meadows KL, Morse MA, Uronis HE, Blobe GC, Hsu SD, Zafar SY, Hurwitz HI.

Invest New Drugs. 2014 Apr;32(2):330-9. doi: 10.1007/s10637-013-0042-9. Epub 2013 Nov 1.

8.

A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.

Uronis HE, Bendell JC, Altomare I, Blobe GC, Hsu SD, Morse MA, Pang H, Zafar SY, Conkling P, Favaro J, Arrowood CC, Cushman SM, Meadows KL, Brady JC, Nixon AB, Hurwitz HI.

Oncologist. 2013;18(3):271-2. doi: 10.1634/theoncologist.2012-0404. Epub 2013 Mar 13.

9.

Tethered olefin studies of alkene versus tetraphenylborate coordination and lanthanide olefin interactions in metallocenes.

Evans WJ, Perotti JM, Brady JC, Ziller JW.

J Am Chem Soc. 2003 Apr 30;125(17):5204-12.

PMID:
12708873
10.

Synthesis of arene-soluble mixed-metal Zr/Ce, Zr/Y, and related [[Zr2(OiPr)9]LnX2]n complexes using the dizirconium nonaisopropoxide ligand.

Evans WJ, Johnston MA, Greci MA, Ansari MA, Brady JC, Ziller JW.

Inorg Chem. 2000 May 15;39(10):2125-9.

PMID:
12526523
11.
12.

Double deprotonation of a cyclopentadienyl alkene to form a polydentate trianionic cyclopentadienyl allyl ligand system.

Evans WJ, Brady JC, Ziller JW.

J Am Chem Soc. 2001 Aug 8;123(31):7711-2. No abstract available.

PMID:
11480999
13.

From nurse to novelist.

Brady JC.

Am J Nurs. 1999 Jan;99(1 Pt 1):60-2. No abstract available.

PMID:
9932059
14.

The mechanism of peroxidase-mediated cytotoxicity. II. Role of the heme moiety.

Lin H, McFaul SJ, Brady JC, Everse J.

Proc Soc Exp Biol Med. 1988 Jan;187(1):7-13.

PMID:
3340620
15.

Antitumour activity of peroxidases.

Everse KE, Lin H, Stuyt EL, Brady JC, Buddingh F, Everse J.

Br J Cancer. 1985 May;51(5):743-6. No abstract available.

Supplemental Content

Loading ...
Support Center